Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences (Nasdaq: TLSA) announced participation at the virtual Biotech Showcase Conference on January 10-12 and 17-19, 2022. Senior management will present and be available for one-on-one meetings throughout the event. Tiziana focuses on innovative drug delivery methods, including nasal, oral, and inhalation routes, to enhance immunotherapy efficacy and safety. Their lead candidates include intranasal foralumab and milciclib, both showing promising clinical results. For more details about the conference, registration is available online.
Tiziana Life Sciences plc has restructured its corporate framework by establishing Tiziana Life Sciences Ltd as its new parent company. This change, formalized on October 20, 2021, involved a two-for-one Share Capital Consolidation, allowing shareholders to maintain their ownership proportions. The newly consolidated shares commenced trading on NASDAQ on the same date. Tiziana continues its focus on developing innovative therapeutics for diseases including cancer, inflammation, and infections, notably progressing with its anti-CD3 monoclonal antibody, Foralumab.
Tiziana Life Sciences plc (NASDAQ: TLSA) has announced a significant corporate restructuring, establishing Tiziana Life Sciences Ltd as the new parent company, effective October 20, 2021. The scheme of arrangement has been sanctioned by the Court, and the Old Tiziana shares will be delisted on October 21, 2021. Following a two-for-one share capital consolidation, the new shares are set to begin trading on NASDAQ. Tiziana specializes in innovative therapeutics for oncology and autoimmune diseases, with upcoming Phase 2 trials for its lead drug, Foralumab.
Tiziana Life Sciences (TLSA) announced that Gabriele Cerrone, the Executive Chairman, increased his shareholding by purchasing 60,000 ordinary shares at 55p each, elevating his total stake from 34.208% to 34.238%. This acquisition occurred on October 4, 2021, and is in line with the UK Takeover Code's regulations. Tiziana focuses on innovative therapeutic developments for conditions including oncology and autoimmune diseases, with upcoming Phase 2 studies for Foralumab in Crohn's Disease and multiple sclerosis.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced the court's sanction of its scheme to reorganize into Tiziana Life Sciences Ltd, a Bermuda-incorporated parent company. The scheme, effective on 20 October 2021, includes a two-for-one share consolidation to enhance share value comparability on NASDAQ. Key dates include the last dealings in Old Tiziana shares on 20 October 2021 and trading commencement for New Tiziana shares on 21 October 2021. The company remains focused on developing therapeutics for oncology, inflammation, and infectious diseases.
Tiziana Life Sciences (Nasdaq: TLSA) recently reported that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 100,000 ordinary shares at 52p each. This purchase increased Cerrone's ownership from 34.078% to 34.129%, just above the 1% threshold set by the UK Takeover Code. Tiziana Life Sciences, focused on innovative therapeutics for oncology and inflammatory diseases, is set to initiate Phase 2 studies for its anti-CD3 monoclonal antibody, Foralumab, for treating Crohn's Disease and multiple sclerosis, furthering its pipeline of treatment options.
Tiziana Life Sciences Plc has initiated a strategic restructuring, transitioning to Tiziana Life Sciences Ltd, a Bermuda-based parent company. This move was approved by Scheme Shareholders with 99.11% support at the Court Meeting and a requisite majority at the General Meeting. The Scheme is pending court sanction on October 19, 2021, with an expected effective date of October 21, 2021. The transition will involve the delisting of Old Tiziana shares from the London Stock Exchange and NASDAQ, paving the way for trading of New Tiziana shares.
Tiziana Life Sciences (NASDAQ: TLSA) announced its interim results for the six months ending June 30, 2021, highlighting significant advancements in therapeutic clinical programs. The Phase 1 study of Foralumab demonstrated immunomodulatory effects, while a study in Brazil showed promising outcomes for COVID-19 patients. The company signed an agreement for a Phase 2 study in severe COVID-19 cases and initiated a study for multiple sclerosis. Financially, Tiziana reported a loss of £12.59 million, with R&D expenses increasing to £12.6 million. The firm had cash reserves of £38.6 million at the period's end.
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) will host a conference call on September 8, 2021, at 4:15 p.m. ET to discuss its exclusive license agreement for evaluating Foralumab, a novel anti-CD3 monoclonal antibody, alongside CAR T candidates for cancer treatment. Interested parties can join via a toll-free line or webcast. A replay will be available until September 22, 2021. Foralumab is recognized for its safety profile in treating autoimmune diseases, making it a significant development in biotechnology.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced the initiation of a strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd in Bermuda as its ultimate parent company. This restructuring, carried out through a scheme of arrangement, aims to enhance the organization’s operational efficiency. Shareholders are invited to virtual meetings on September 27, 2021, to vote on the scheme. Key dates include the effective date for the scheme on October 21, 2021, and the delisting of Old Tiziana Shares and ADSs on the same day.